Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.08 +0.39 (+3.34%)
Streaming Delayed Price Updated: 1:42 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump ↗
Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
30 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021 ↗
Upgrades According to Raymond James, the prior rating for Roper Technologies Inc (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 30.07% to $3.59 during Monday's pre-market session. The market value of their outstanding shares is at $137.3... 
Via Benzinga
News headline image
54 Biggest Movers From Friday ↗
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher ↗
Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Stocks Mixed as Investors Try to Brush Off Economic Anxieties ↗
The Dow Jones Industrial Average is up 204 points at midday, after trading sideways this morning as September's anxieties over inflation and slowing economic growth continue to grip Wall Street. 
Via Talk Markets
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume... 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet ↗
Midway through trading Friday, the Dow traded up 0.88% to 34,141.74 while the NASDAQ rose 0.12% to 14,465.49. The S&P also rose, gaining 0.58% to 4,332.44. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Here's Why Omeros Stock Is Tanking Today ↗
The narsoplimab program hasn't proceeded as swimmingly as investors thought. 
Via The Motley Fool
News headline image
Why Are Omeros Shares Plunging On Friday? ↗
The FDA has identified deficiencies regarding Omeros Corporation's (NASDAQ: OMER) marketing application of narsoplimab for hematopoietic stem cell transplant-associated... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September ↗
Following the market opening Friday, the Dow traded up 0.49% to 34,010.27 while the NASDAQ fell 0.23% to 14,415.00. The S&P also rose, gaining 0.16% to 4,314.50. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Why Omeros Stock Is Plummeting This Week ↗
The biotech stock was part of a larger Wall Street sell-off. 
Via The Motley Fool
News headline image
Looking Into Omeros's Return On Capital Employed ↗
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $... 
Via Benzinga
News headline image
Omeros: Q2 Earnings Insights ↗
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to... 
Via Benzinga
News headline image
Omeros Corporation Reports Second Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021 ↗
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
From Omeros Corporation
Via Business Wire
News headline image
Earnings Scheduled For August 9, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
News headline image
Return On Capital Employed Overview: Omeros ↗
Omeros (NASDAQ:OMER) reported Q1 sales of $21.06 million. Earnings fell to a loss of $30.61 million, resulting in a 9.47% decrease from last quarter. In Q4, Omeros brought in $10.... 
Via Benzinga
News headline image
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients ↗
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of... 
Via Benzinga
News headline image
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
From Omeros Corporation
Via Business Wire
News headline image
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
From Omeros Corporation
Via Business Wire
News headline image
Omeros: Return On Capital Employed Insights ↗
Omeros (NASDAQ:OMER) reported Q1 sales of $21.06 million. Earnings fell to a loss of $30.61 million, resulting in a 9.47% decrease from last quarter. Omeros collected $10.63... 
Via Benzinga
News headline image
Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients ↗
Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.